Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic Biosciences Ltd (PBL), a UK subsidiary of ProMetic Life Sciences Inc, has entered into an agreement with a multinational firm for enhancing its quality of a biopharmaceutical product which is manufactured in multi-ton quantities.
Subscribe to our email newsletter
As per the terms of the agreement, ProMetic will be responsible to accelerate an affinity resin product and associated manufacturing process conditions for its client.
The agreement will provide ProMetic with initial service revenues of up to CAD800,000 during 2011 and anticipated to lead to a subsequent long-term agreement for the manufacture and supply of the affinity resin when related target product profiles are achieved.
PBL CEO Steve Burton said ProMetic’s affinity technology has many potential uses as demonstrated by this latest application where a purpose-designed affinity product will be used to target and remove specific impurities from an existing biopharmaceutical product to further enhance its quality and safety.
"The large annual production of this biopharmaceutical product and the frequency of batch manufacture should ensure a regular demand for ProMetic’s resin," Burton said.